turnaround progress margin headwind
come easi comp led us believ result
beatabl top-lin fell in-lin street ep cent
higher would satisfi investor view sentiment
hamper commentari relat specif on-going margin
pressur lost sale zbh distribut agreement
bonesupport bonex-om rate underli revenue growth
y/i improv q/q y/i help tender
estimate soft expect management commentari
indic on-going margin pressur along increas fx
headwind collect headwind lower ep off-set
lower interest expens tax rate net net make
progress segment remain compel valuat
maintain neutral rate continu see limit upsid due
on-going margin pressur suppli constraint hamper sale
growth regulatori risk on-go fda discuss
rosa track await fda approv management announc
first rosa tka procedur perform australia
declar platform ahead schedul compani still
await fda approv knee spine applic
us beyond current approv brain applic upon approv
unit either spine brain function includ current
instal brain unit knee function potenti
futur three avail singl unit management note
launch requir increas invest though
get leaner get stronger management note breadth
portfolio clear need undergo sku
ration improv effici suppli chain like
help margin growth time need done
measur pace order limit custom disrupt midst on-
go suppli constraint limit margin upsid view
valuat zimmer biomet rate neutral btig
publish price target neutral rate stock
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
zimmer biomet report result overal revenu came
top btig/consensu expect call
respect segment report revenu
knee hip dental spine
 cmf compar btig/consensu estim
organ revenu growth expect
sequenti last quarter gross margin
adjust bp estim cost associ qualiti
remedi north warsaw campu impact line sg
percentag revenu came versu expect call
revenu versu expect told
adjust ep quarter versu btig/consensu estim
call lower interest expens better tax rate drove
made follow chang model
actualsbtig estimate variancetot net bpssg spend bpsr spend bpsadj ebit bpsadj ebitda bpstax bpssourc btig research estim compani filingsvari
within zbh revenu mix adjust specif segment account
sale dynam management spoke today earn call specif
within expect loss sale
termin distribut agreement bonesupport ab
revenu categori believ lost sale persist first
quarter although improv sequenti taken
categori management expect addit
due time tender order book adjust
revenu primarili within categori account
pull-forward tender book sum revenu
estim lower forward revenu estim also
lower
 adjust gm expect remain flat
improv previou expect faster
improv combin dynam
also increas sg expect slightli
om expans less like occur management commentari today
result om smaller improv
lower interest expens lower tax rate partial off-set
dynam ep headwind management spoke off-set
view improv interest expens tax believ
may opportun interest tax get back ep
headwind well wait management commentari guidanc adjust
lower
zimmer biomet rate neutral zimmer biomet trade
estim next twelv month ep project versu comp
group forecast revenu compound-annual-growth-rate
comp group forecast ep compound-annual-growth-rate
also comp group feel discount
overal comp group warrant given zimmer biomet current top-lin
growth expect near-term challeng associ product
qualiti remedi persist margin pressur btig
publish price target neutral rate stock risk rate includ
follow upsid perspect shorter organiz turnaround
assum less regulatori challeng assum faster resolut
on-go qualiti remedi lack gm pressur strong uptak robot
better expect employe moral stronger expect price
pressur downsid perspect loss market share
btig research estim compani filingsnewold chang
addit regulatori requir cost limit robot adopt
longer expect improv compani cultur
incom etot y/i sale special oper incom incom tax expens net share net incom share gross net net oper tax expens btig research estim compani report
revenu y/i btig research estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
